The vaccine market is one of the most activcquisition spaces in the pharmaceutical industry today. Major market players for vaccine therapies are GlaxoSmithKline, Merck, Sanofi-Aventis, Sanofi-Pasteur, Wyeth, and Novartis. Furthermore, GlaxoSmithKline, Merck and Sanofi-Aventis control approximately 60% of the global vaccine market. Worldwide revenues in the vaccine market were reported to be $23 billion in 2008 and are projected to reach $4 billion by 2012, while the cancer vaccine market is projected to exceed $8 billion. Peptagen’s portfolio addresses large global markets in cancer, HIV/AIDS and other pathogenic diseas es; all highly visible and extremely profitable

In the United States alone, more than 22,000 Americans succumb to AIDS each year. Hospitalizations for AIDS related illness exceed 185,000 annually, representing billions of dollars in annual health care costs. Current HAART regimens have slowed the progression of HIV to AIDS, While this is a significant improvement over the pre-HAART era mortality rate of 40%; a significant need still exists for an effective immune-based therapy. Peptagen intends to initially develop a chronically administered therapeutic nanoparticle vaccine to treat HIV in subjects with AIDS defining illness. This treatment is anticipated to be nasally administered intermittently (every few weeks) on a chronic schedule. In addition to the treatment of acute AIDS related illness, the vaccine may be beneficial in clearing occult virus during periods of active viral budding. Peptagen’s technology also has broad implications for the is the use of maintenance tumoristatic agents. These drugs are administered chronically to delay the progression of tumors. As a class of oncology therapeutics, biologic angiostatic treatments for cancer exceed $15 billion annually.


©2010 Peptagen, Inc. All Rights Reserved
Home | About Us | Technology | Markets | News | Contact Us